Protein-based cardiogenic shock patient classifier.


Journal

European heart journal
ISSN: 1522-9645
Titre abrégé: Eur Heart J
Pays: England
ID NLM: 8006263

Informations de publication

Date de publication:
21 08 2019
Historique:
received: 11 11 2018
revised: 04 01 2019
accepted: 19 04 2019
pubmed: 18 6 2019
medline: 22 10 2020
entrez: 18 6 2019
Statut: ppublish

Résumé

Cardiogenic shock (CS) is associated with high short-term mortality and a precise CS risk stratification could guide interventions to improve patient outcome. Here, we developed a circulating protein-based score to predict short-term mortality risk among patients with CS. Mass spectrometry analysis of 2654 proteins was used for screening in the Barcelona discovery cohort (n = 48). Targeted quantitative proteomics analyses (n = 51 proteins) were used in the independent CardShock cohort (n = 97) to derive and cross-validate the protein classifier. The combination of four circulating proteins (Cardiogenic Shock 4 proteins-CS4P), discriminated patients with low and high 90-day risk of mortality. CS4P comprises the abundances of liver-type fatty acid-binding protein, beta-2-microglobulin, fructose-bisphosphate aldolase B, and SerpinG1. Within the CardShock cohort used for internal validation, the C-statistic was 0.78 for the CardShock risk score, 0.83 for the CS4P model, and 0.84 (P = 0.033 vs. CardShock risk score) for the combination of CardShock risk score with the CS4P model. The CardShock risk score with the CS4P model showed a marked benefit in patient reclassification, with a net reclassification improvement (NRI) of 0.49 (P = 0.020) compared with CardShock risk score. Similar reclassification metrics were observed in the IABP-SHOCK II risk score combined with CS4P (NRI =0.57; P = 0.032). The CS4P patient classification power was confirmed by enzyme-linked immunosorbent assay (ELISA). A new protein-based CS patient classifier, the CS4P, was developed for short-term mortality risk stratification. CS4P improved predictive metrics in combination with contemporary risk scores, which may guide clinicians in selecting patients for advanced therapies.

Identifiants

pubmed: 31204432
pii: 5519422
doi: 10.1093/eurheartj/ehz294
doi:

Substances chimiques

Blood Proteins 0
Proteome 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2684-2694

Commentaires et corrections

Type : CommentIn

Informations de copyright

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.

Auteurs

Ferran Rueda (F)

Heart Institute, Hospital Universitari Germans Trias i Pujol, c/ Canyet SN, 08916 Badalona, Spain.
Department of Medicine, CIBERCV, Autonomous University of Barcelona, Barcelona, Spain.

Eva Borràs (E)

Proteomics Unit, Centre de Regulació Genòmica (CRG), Barcelona Institute of Science and Technology (BIST), Dr Aiguader 88, Barcelona, Spain.
Universitat Pompeu Fabra (UPF), Dr Aiguader 88, Barcelona, Spain.

Cosme García-García (C)

Heart Institute, Hospital Universitari Germans Trias i Pujol, c/ Canyet SN, 08916 Badalona, Spain.
Department of Medicine, CIBERCV, Autonomous University of Barcelona, Barcelona, Spain.

Oriol Iborra-Egea (O)

Heart Institute, Hospital Universitari Germans Trias i Pujol, c/ Canyet SN, 08916 Badalona, Spain.
Department of Medicine, CIBERCV, Autonomous University of Barcelona, Barcelona, Spain.

Elena Revuelta-López (E)

Heart Institute, Hospital Universitari Germans Trias i Pujol, c/ Canyet SN, 08916 Badalona, Spain.
Department of Medicine, CIBERCV, Autonomous University of Barcelona, Barcelona, Spain.

Veli-Pekka Harjola (VP)

Emergency Medicine, Department of Emergency Medicine and Services, University of Helsinki, Helsinki University Hospital, Finland.

Germán Cediel (G)

Heart Institute, Hospital Universitari Germans Trias i Pujol, c/ Canyet SN, 08916 Badalona, Spain.
Department of Medicine, CIBERCV, Autonomous University of Barcelona, Barcelona, Spain.

Johan Lassus (J)

Cardiology, University of Helsinki, Heart and Lung Center, Helsinki University Hospital, Finland.

Tuukka Tarvasmäki (T)

Cardiology, University of Helsinki, Heart and Lung Center, Helsinki University Hospital, Finland.

Alexandre Mebazaa (A)

U942 Inserm, University Paris Diderot, APHP Hôpitaux Universitaires Saint-Louis-Lariboisière, INI-CRCT, Paris, France.

Eduard Sabidó (E)

Proteomics Unit, Centre de Regulació Genòmica (CRG), Barcelona Institute of Science and Technology (BIST), Dr Aiguader 88, Barcelona, Spain.
Universitat Pompeu Fabra (UPF), Dr Aiguader 88, Barcelona, Spain.

Antoni Bayés-Genís (A)

Heart Institute, Hospital Universitari Germans Trias i Pujol, c/ Canyet SN, 08916 Badalona, Spain.
Department of Medicine, CIBERCV, Autonomous University of Barcelona, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH